肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

抗体-药物偶联物（曲妥珠单抗-deruxtecan）治疗早期乳腺癌

2019-05-28 不详 网络

抗体-药物偶联物曲妥珠单抗deruxtecan
关注

阿斯利康的肿瘤研发部门负责人José Baselga表示：“阿斯利康将发展新型抗癌药物，以针对早期癌症而非晚期癌症。我们需要把更多资源花在那些可以治愈的早期癌症之上”。

阿斯利康的肿瘤研发部门负责人José Baselga表示：“阿斯利康将发展新型抗癌药物，以针对早期癌症而非晚期癌症。我们需要把更多资源花在那些可以治愈的早期癌症之上”。

José Baselga表示，阿斯利康将在今年晚些时候开始测试HER2靶向抗体-药物偶联物（曲妥珠单抗-deruxtecan），也称为DS-8201，用于治疗早期乳腺癌。该公司及合作伙伴Daiichi Sankyo最近报道，对于先前用罗氏Kadcyla（曲妥珠单抗）治疗的HER2阳性转移性乳腺癌患者，II期DESTINY-Breast01试验表明，曲妥珠单抗-deruxtecan的治疗已经达到其主要终点。


原始出处：

http://www.firstwordpharma.com/node/1643193#axzz5pAuKW7uK

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1646577, encodeId=e65a16465e7f0, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Sat Mar 21 07:43:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952121, encodeId=aa38195212198, content=<a href='/topic/show?id=e56658621e' target=_blank style='color:#2F92EE;'>#deruxtecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5862, encryptionId=e56658621e, topicName=deruxtecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Mon Jun 17 13:43:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652343, encodeId=edc61652343a4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Aug 13 14:43:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648145, encodeId=d747164814549, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sun Jan 19 11:43:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
    2020-03-21 lvygwyt2789

    #抗体-药物偶联物#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1646577, encodeId=e65a16465e7f0, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Sat Mar 21 07:43:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952121, encodeId=aa38195212198, content=<a href='/topic/show?id=e56658621e' target=_blank style='color:#2F92EE;'>#deruxtecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5862, encryptionId=e56658621e, topicName=deruxtecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Mon Jun 17 13:43:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652343, encodeId=edc61652343a4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Aug 13 14:43:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648145, encodeId=d747164814549, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sun Jan 19 11:43:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
    2019-06-17 dangious

    #deruxtecan#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1646577, encodeId=e65a16465e7f0, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Sat Mar 21 07:43:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952121, encodeId=aa38195212198, content=<a href='/topic/show?id=e56658621e' target=_blank style='color:#2F92EE;'>#deruxtecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5862, encryptionId=e56658621e, topicName=deruxtecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Mon Jun 17 13:43:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652343, encodeId=edc61652343a4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Aug 13 14:43:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648145, encodeId=d747164814549, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sun Jan 19 11:43:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
    2019-08-13 shock_melon

    #TEC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1646577, encodeId=e65a16465e7f0, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Sat Mar 21 07:43:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952121, encodeId=aa38195212198, content=<a href='/topic/show?id=e56658621e' target=_blank style='color:#2F92EE;'>#deruxtecan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5862, encryptionId=e56658621e, topicName=deruxtecan)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Mon Jun 17 13:43:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652343, encodeId=edc61652343a4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Aug 13 14:43:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648145, encodeId=d747164814549, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sun Jan 19 11:43:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
    2020-01-19 linlin2320

    #曲妥珠#

    0

相关资讯

Alteogen的抗体-药物偶联物获得FDA孤儿药物认定用于胃癌治疗

韩国制药公司Alteogen近日宣布，抗体-药物偶联物（ALT-P7）已成功获得美国食品和药物管理局（FDA）的孤儿药认定资格，用于治疗胃癌。ALT-P7是一种抗体-药物偶联物（ADC），ALT-P7的抗体部分使用的是曲妥珠单抗类似抗体。这一批准将保证Alteogen在FDA批准ALT-P7上市后的七年市场独占权。

抗体-药物偶联物：加拿大批准ADCETRIS与AVD联合化疗用于初治型晚期霍奇金淋巴瘤

Seattle基因公司近日宣布，加拿大卫生部已批准其补充新药申请，允许ADCETRIS（brentuximab vedotin）与AVD（阿霉素、长春碱和达卡巴嗪）联合化疗用于初治型晚期霍奇金淋巴瘤（HL）患者。